electroCore announced the results of a Truvaga focus group study conducted earlier this year. Based on a 30-day in-home use test by an independent third-party research firm, the Truvaga product helped its users improve stress, anxiety, sleep, energy, and mood. In the in-home focus group study, 34 participants were instructed to use the Truvaga product twice a day for 30 days to assess the product’s benefits and overall user experience. Self-assessment evaluations were reported after 7 and 30 days. After 30 days, users reported the following: 94% felt calmer; 91% felt their mood improved; 88% felt less anxious; 85% felt an improvement in stress; 82% felt more alert; 77% had more energy; and 74% felt they sleep better. After the study was completed, 86% of users said they will continue to use the product for ongoing overall wellness benefits. "I am thrilled about the initial launch of our wellness product, Truvaga," stated Michael Mansfield, VP, Marketing at electroCore. "The initial response and testimonials we received are a reminder of the benefits that can be realized by using vagus nerve stimulation and I look forward to building the Truvaga brand during 2023 through ecommerce and affiliate channels."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ECOR:
- electroCore Affirms No Direct Exposure to Silicon Valley Bank, Silvergate Bank, or Signature Bank
- electroCore reports no direct exposure to SVB, Silvergate, Signature Bank
- electroCore target adjusted on 1-for-15 reverse-split at H.C. Wainwright
- electroCore reports Q4 EPS ($1.22), consensus ($1.12)
- electroCore Announces Fourth Quarter and Full Year 2022 Financial Results
